Aktis Oncology Statistics
Total Valuation
Aktis Oncology has a market cap or net worth of $874.89 million. The enterprise value is $368.81 million.
| Market Cap | 874.89M |
| Enterprise Value | 368.81M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aktis Oncology has 55.62 million shares outstanding. The number of shares has increased by 3,649.41% in one year.
| Current Share Class | 53.75M |
| Shares Outstanding | 55.62M |
| Shares Change (YoY) | +3,649.41% |
| Shares Change (QoQ) | +13.72% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 43.34% |
| Float | 28.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 86.97 |
| Forward PS | 112.00 |
| PB Ratio | 1.79 |
| P/TBV Ratio | 1.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 36.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.33, with a Debt / Equity ratio of 0.02.
| Current Ratio | 16.33 |
| Quick Ratio | 16.17 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -16.59% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $127,342 |
| Profits Per Employee | -$925,823 |
| Employee Count | 79 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 21.41 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 31.43 |
| Average Volume (20 Days) | 343,753 |
Short Selling Information
The latest short interest is 4.72 million, so 8.48% of the outstanding shares have been sold short.
| Short Interest | 4.72M |
| Short Previous Month | 3.25M |
| Short % of Shares Out | 8.48% |
| Short % of Float | 16.49% |
| Short Ratio (days to cover) | 10.11 |
Income Statement
In the last 12 months, Aktis Oncology had revenue of $10.06 million and -$73.14 million in losses. Loss per share was -$2.77.
| Revenue | 10.06M |
| Gross Profit | -68.22M |
| Operating Income | -87.18M |
| Pretax Income | -73.14M |
| Net Income | -73.14M |
| EBITDA | -84.36M |
| EBIT | -87.18M |
| Loss Per Share | -$2.77 |
Balance Sheet
The company has $517.32 million in cash and $11.24 million in debt, with a net cash position of $506.08 million or $9.10 per share.
| Cash & Cash Equivalents | 517.32M |
| Total Debt | 11.24M |
| Net Cash | 506.08M |
| Net Cash Per Share | $9.10 |
| Equity (Book Value) | 484.84M |
| Book Value Per Share | 8.76 |
| Working Capital | 492.41M |
Cash Flow
In the last 12 months, operating cash flow was -$75.29 million and capital expenditures -$9.27 million, giving a free cash flow of -$84.57 million.
| Operating Cash Flow | -75.29M |
| Capital Expenditures | -9.27M |
| Depreciation & Amortization | 2.82M |
| Net Borrowing | n/a |
| Free Cash Flow | -84.57M |
| FCF Per Share | -$1.52 |
Margins
| Gross Margin | n/a |
| Operating Margin | -866.63% |
| Pretax Margin | -727.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Aktis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3,649.41% |
| Shareholder Yield | -3,649.41% |
| Earnings Yield | -17.61% |
| FCF Yield | -9.67% |
Analyst Forecast
The average price target for Aktis Oncology is $35.39, which is 124.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.39 |
| Price Target Difference | 124.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 13.56% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Aktis Oncology has an Altman Z-Score of 8.98 and a Piotroski F-Score of 2.
| Altman Z-Score | 8.98 |
| Piotroski F-Score | 2 |